Liposomal Co-Delivery of Omacetaxine Mepesuccinate and Doxorubicin for Synergistic Potentiation of Antitumor Activity

[1]  T. Minko,et al.  Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[2]  Susan O'Brien,et al.  Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval. , 2013, Clinical lymphoma, myeloma & leukemia.

[3]  H. Kantarjian,et al.  Omacetaxine mepesuccinate (synribo) – newly launched in chronic myeloid leukemia , 2013, Expert opinion on pharmacotherapy.

[4]  M. Espié,et al.  Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Yunfang Li,et al.  Overexpression of Mcl-1 Confers Multidrug Resistance, Whereas Topoisomerase IIβ Downregulation Introduces Mitoxantrone-Specific Drug Resistance in Acute Myeloid Leukemia , 2013, Molecular Pharmacology.

[6]  Ronit Satchi-Fainaro,et al.  Nano-sized polymers and liposomes designed to deliver combination therapy for cancer. , 2013, Current opinion in biotechnology.

[7]  G. Braunstein,et al.  Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer , 2013, Journal of Cancer Research and Clinical Oncology.

[8]  Chi‐Hwa Wang,et al.  Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma. , 2013, Biomaterials.

[9]  J. Mössner,et al.  New and emerging combination therapies for esophageal cancer , 2013, Cancer management and research.

[10]  Shirui Mao,et al.  Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. , 2013, ACS nano.

[11]  Hyunseung Lee,et al.  Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. , 2013, Cancer letters.

[12]  L. Andĕra,et al.  The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms , 2013, Apoptosis.

[13]  Jin-jian Lu,et al.  Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells , 2013, Pharmacological reports : PR.

[14]  H. Uludaǧ,et al.  Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells , 2013, Cancer Gene Therapy.

[15]  Y. Oh,et al.  Enhanced Intrapulmonary Delivery of Anticancer siRNA for Lung Cancer Therapy Using Cationic Ethylphosphocholine-based Nanolipoplexes , 2013, Molecular Therapy.

[16]  K. Joshi,et al.  Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells , 2013, BMC Cancer.

[17]  S. W. Kim,et al.  Paclitaxel-conjugated PEG and arginine-grafted bioreducible poly (disulfide amine) micelles for co-delivery of drug and gene. , 2012, Biomaterials.

[18]  J. Nemunaitis,et al.  Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors , 2012, Cancer Chemotherapy and Pharmacology.

[19]  Dong Eun Kim,et al.  HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells. , 2012, Anticancer research.

[20]  A. Attia,et al.  Advanced Materials for Co‐Delivery of Drugs and Genes in Cancer Therapy , 2012, Advanced healthcare materials.

[21]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Y. Kagami,et al.  Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low–intermediate risk, aggressive non-Hodgkin’s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508 , 2012, International Journal of Hematology.

[23]  Maria A. Rodriguez,et al.  Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. , 2012, Blood.

[24]  M. Yeh,et al.  Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy , 2011, International journal of nanomedicine.

[25]  Hongbo Zhu,et al.  Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors , 2011, BMC Cancer.

[26]  P. le Coutre,et al.  Omacetaxine mepesuccinate for the treatment of leukemia , 2011, Expert opinion on pharmacotherapy.

[27]  Young Bong Kim,et al.  Enhanced tumor localization and retention of chlorin e6 in cationic nanolipoplexes potentiate the tumor ablation effects of photodynamic therapy , 2011, Nanotechnology.

[28]  Young Bong Kim,et al.  Enhanced transfection rates of small-interfering RNA using dioleylglutamide-based magnetic lipoplexes. , 2011, Nucleic acid therapeutics.

[29]  P. Russell,et al.  Molecular Chemotherapy and Chemotherapy: A New Front against Late-Stage Hormone-Refractory Prostate Cancer , 2011, Clinical Cancer Research.

[30]  T. Holyoake,et al.  Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells , 2011, Leukemia.

[31]  Kwangmeyung Kim,et al.  Reduced dose-limiting toxicity of intraperitoneal mitoxantrone chemotherapy using cardiolipin-based anionic liposomes. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[32]  C. Scott,et al.  Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance. , 2010, Blood.

[33]  Erinna F. Lee,et al.  The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia , 2009, Leukemia.

[34]  S. Lowe,et al.  Altering Chemosensitivity by Modulating Translation Elongation , 2009, PloS one.

[35]  I. Hwang,et al.  Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer. , 2008, Lung cancer.

[36]  C Haanen,et al.  A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. , 1995, Journal of immunological methods.

[37]  P. Cullis,et al.  Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.

[38]  T. Hibi,et al.  Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells , 2012, Gastric Cancer.

[39]  Meir Wetzler,et al.  Omacetaxine as an anticancer therapeutic: what is old is new again. , 2011, Current pharmaceutical design.